Novel combinations based on epidermal growth factor receptor inhibition

Clinical Cancer Research

Volumn 12, Issue 14, 2006, Pages

  Adjei, Alex A ^a   Lynch, Thomas ^b   Eisen, Tim ^b   Goss, Glenwood ^b   Sandler, Alan ^b   Heymach, John ^b   Johnson, Bruce ^b   Engelman, Jeffrey ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; TIPIFARNIB; VASCULOTROPIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; ENZYME BLOOD LEVEL; EPITHELIUM TUMOR; FATIGUE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RAF KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33746864883     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0623     Document Type: Conference Paper

References (29)

1. Teicher BA, Herman TS, Holden SA, Eder JP. Chemotherapeutic potentiation through interaction at the level of DNA. In: Chou T-C, Rideout DC, editors. Synergism and antagonism in chemotherapy. Orlando (FL): Academic Press; 1991. p. 541-83.
2. Teicher BA. Assays for in vitro and in vivo synergy. In: Buolamwini J, Adjei AA, editors. Methods in molecular medicine: novel anticancer drug protocols. Totowa (NJ). Humana Press; 2004. p. 297-341.
3. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
4. Chou JH. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: Chou T-C, Rideout DC, editors. Synergism and antagonism in chemotherapy. Orlando (FL): Academic Press; 1991. p. 223-41.
5. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141.
6. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37.
7. Hsuan JJ, Tan SH. Growth factor-dependent phosphoinositide signaling. Int J Biochem Cell Biol 1997;29:415-35.
8. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
9. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26.
10. Khoshyomn S, Penar PL, Rossi J, Wells A, Abramson DL, Bhushan A. Inhibition of phospholipase C-gamma1 activation blocks glioma cell motility and invasion of fetal rat brain aggregates. Neurosurgery 1999;44:568-77.
11. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005;23:5386-403.
12. Steinbach JP, Klumpp A, Wolburg H, Weller M. Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res 2004;64:1575-8.
13. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7.
14. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91-9.
15. Nobukuni T, Joaquin M, Roccio M, et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A 2005;102:14238-43.
16. Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM, Drabkin HA. Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer 2005;92:2266-77.
17. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
18. Magne N, Fischel JL, Dubreuil A, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839. Br J Cancer 2002;86:1518-23.
19. Ma CX, Croghan G, Reid J, et al. A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors [abstract 3000]. Proc Am Soc Clin Oncol 2005;24.
20. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
21. Goldman CK, Kim J, Wong WL, et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4:121-33.
22. Maity A, Pore N, Lee J, et al. Epidermal growth factor receptor transcriptionally upregulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-86.
23. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
24. Viloria-Petit AM, Rak J, Hung M-C, et al. Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am J Pathol 1997;151:1523-30.
25. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
26. Herbst RS, Johnson DH, Mininberg E. et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55.
27. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
28. Vincent P, Zhang X, Chen C, et al. [abstract 719]. Proc Am Assoc Cancer Res 2003:44.
29. Adjei AA, Mandrekar S, Marks RS, et al. A Phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) [abstract 3067]. Proc Am Soc Clin Oncol 2005:24.